Marijuana’s Promise Of Profit Remains Elusive (For Now)

Those trials are all ongoing, so investors will need to rely on past trial data to make judgments on whether or not the market demand for GW Pharma's medicine will justify the company's $1.27 billion market cap.

NEW YORK: Excitement surrounding medical marijuana led to a significant run-up in GW Pharmaceuticals‘ share price earlier this year, but based on the company’s recently announced quarterly and fiscal full-year earnings results, the promise of marijuana profit remains far off in the distance. Planning for the future That’s because GW Pharma has only one marketed marijuana derived therapy, Read the full article…